
      FDA approves new drug that may help stop a rare, fatal condition that doctors call a ‘ticking time bomb’
    

This article follows the story of Katrina Barry, who was diagnosed with pulmonary arterial hypertension (PAH) at age 25.

She was given two to five years to live before joining a study for an experimental drug called sotatercept.

The drug improved her condition, allowing her to resume activities and live a more normal life.

The FDA recently approved the medication, offering hope to others with PAH.

However, there are side effects and unknowns regarding its long-term effectiveness.

